Recro Pharma, Inc. (NASDAQ:REPH) Announces Earnings Results
Recro Pharma, Inc. (NASDAQ:REPH) released its earnings results on Thursday. The specialty pharmaceutical company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.06, MarketWatch Earnings reports. Recro Pharma had a negative return on equity of 61.09% and a negative net margin of 45.15%. The business had revenue of $16.93 million for the quarter, compared to analyst estimates of $14.90 million.
Recro Pharma (REPH) traded up 0.68% during mid-day trading on Friday, reaching $7.35. The company’s stock had a trading volume of 31,500 shares. The stock’s market cap is $140.02 million. The firm’s 50 day moving average price is $7.37 and its 200 day moving average price is $7.64. Recro Pharma has a 12-month low of $5.81 and a 12-month high of $10.85.
In related news, major shareholder James E. Flynn sold 10,000 shares of the stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $6.74, for a total transaction of $67,400.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider James E. Flynn sold 62,868 shares of the stock in a transaction dated Thursday, June 8th. The stock was sold at an average price of $7.06, for a total value of $443,848.08. The disclosure for this sale can be found here. In the last three months, insiders have sold 215,762 shares of company stock worth $1,430,830. 21.60% of the stock is owned by corporate insiders.
A number of research firms have weighed in on REPH. Roth Capital set a $20.00 target price on Recro Pharma and gave the stock a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies set a $11.00 target price on Recro Pharma and gave the stock a “buy” rating in a research note on Tuesday, July 25th. Zacks Investment Research lowered Recro Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, July 13th. Finally, Janney Montgomery Scott lowered Recro Pharma from a “buy” rating to a “fair value” rating and reduced their target price for the stock from $21.00 to $6.50 in a research note on Wednesday, June 14th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $14.00.
COPYRIGHT VIOLATION NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/08/11/recro-pharma-inc-nasdaqreph-announces-earnings-results.html.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.